Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
JP1 normalizes tumor vasculature to suppress metastasis and facilitate drug delivery by inhibiting IL-8
Jiahua Cui, Zhen Che, Lu Zou, Dongyin Chen, Zhan Xie, Kun Ding, Huning Jiang, Aiping Li, Jianwei Zhou, Yongqian Shu
Jiahua Cui, Zhen Che, Lu Zou, Dongyin Chen, Zhan Xie, Kun Ding, Huning Jiang, Aiping Li, Jianwei Zhou, Yongqian Shu
View: Text | PDF
Research Article Angiogenesis Oncology

JP1 normalizes tumor vasculature to suppress metastasis and facilitate drug delivery by inhibiting IL-8

  • Text
  • PDF
Abstract

Tumor vascular normalization prevents tumor cells from breaking through the basement membrane and entering the vasculature, thereby inhibiting metastasis initiation. In this study, we report that the antitumor peptide JP1 regulated mitochondrial metabolic reprogramming through AMPK/FOXO3a/UQCRC2 signaling, which improved the tumor microenvironment hypoxia. The oxygen-rich tumor microenvironment inhibited the secretion of IL-8 by tumor cells, thereby promoting tumor vascular normalization. The normalized vasculature resulted in mature and regular blood vessels, which made the tumor microenvironment form a benign feedback loop consisting of vascular normalization, sufficient perfusion, and an oxygen-rich microenvironment, prevented tumor cells from entering the vasculature, and inhibited metastasis initiation. Moreover, the combined therapy of JP1 and paclitaxel maintained a certain vascular density in the tumor and promoted tumor vascular normalization, increasing the delivery of oxygen and drugs and enhancing the antitumor effect. Collectively, our work highlights the antitumor peptide JP1 as an inhibitor of metastasis initiation and its mechanism of action.

Authors

Jiahua Cui, Zhen Che, Lu Zou, Dongyin Chen, Zhan Xie, Kun Ding, Huning Jiang, Aiping Li, Jianwei Zhou, Yongqian Shu

×

Figure 4

JP1 promotes tumor oxidative phosphorylation and improves tumor microenvironment hypoxia.

Options: View larger image (or click on image) Download as PowerPoint
JP1 promotes tumor oxidative phosphorylation and improves tumor microenv...
(A and B) The oxidative phosphorylation level of B16F10 (A) and LLC (B) cells was assessed by OCR analysis after treatment with indicated concentrations of JP1 for 48 hours (n = 5). (C and D) Representative immunohistochemical staining of HIF1α in the B16F10 tumor nodules (C). Quantification of HIF1α intensity (D) (n = 6). (E and F) Representative immunohistochemical staining of HIF1α in the LLC tumor nodules (E). Quantification of HIF1α intensity (F) (n = 6). Scale bars: 100 μm (C and E). The solid boxes are further magnified by 8.6×. (G and H) HIF1α was assessed by Western blot after treatment with indicated concentrations of JP1 for 48 hours in B16F10 (G) and LLC (H) cells (n = 3). (I and J) HIF1α protein extracted from B16F10 (I) and LLC (J) tumor nodules was assessed by Western blot; quantitation of HIF1α protein concentrations is shown (n = 6). **P < 0.01; ***P < 0.001 by unpaired, 2-tailed Student’s t test (D, F, I, and J) or ordinary 1-way ANOVA (G and H).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts